Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

MSKCC/Motzer Score Calculator

Karnofsky Performance Status <80%

Hemoglobin Below Lower Limit of Normal

Corrected Calcium >10 mg/dL (>2.5 mmol/L)

LDH >1.5× Upper Limit of Normal

No Prior Nephrectomy

Motzer Score: –

Awaiting input

Select all criteria to compute the score.

Predicts survival based on clinical and laboratory data in metastatic RCC patients.

Why Use

Assists clinicians in discussions about prognosis for patients with metastatic RCC and can be used as a stratification factor in clinical trials.

When to Use

Patients with metastatic RCC undergoing systemic therapy and being considered for clinical trial enrollment, and in clinical practice for the estimation of prognosis.

Formula

Addition of selected points, as above.

Pearls / Pitfalls

Initially created in the pre-targeted therapy era of RCC, but has since been validated in patients receiving targeted therapy ( Heng 2013 ). Multiple other models have since been established based on the MSKCC/Motzer score, including: Mekhail Extension of the Motzer Score IMDC (International Metastatic RCC Database Consortium) Risk Model May assist in estimating prognosis of patients with metastatic RCC, but is not currently used for making decisions about treatment (use IMDC Risk Model instead). Easy to use and uses readily available clinical and laboratory variables.

Management

The score is currently not used for treatment decision-making. The IMDC Risk Model , which was originally based on the MSKCC/Motzer score, is currently used in treatment decision-making for metastatic RCC ( NCCN Guidelines 2019) .

Critical Actions

Can only be applied to patients with metastatic RCC that receive systemic therapy.

More Information

Interpretation: Score Risk Median survival 0 Good 20 months 1-2 Intermediate 10 months ≥3 High 4 months